Bank of New York Mellon Corp - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is and the CUSIP is 761330AB5. A total of 24 filers reported holding REVANCE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$162,366
-23.5%
200,0000.0%0.00%
Q2 2023$212,272
-13.9%
200,0000.0%0.00%
Q1 2023$246,480
+145.9%
200,000
+100.0%
0.00%
Q4 2022$100,250
-68.1%
100,000
-66.7%
0.00%
Q3 2022$314,000300,0000.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Context Capital Management, LLC 20,087$23,535,0002.18%
ZAZOVE ASSOCIATES LLC 15,910,000$18,551,0001.66%
SSI INVESTMENT MANAGEMENT LLC 4,487,000$5,231,0000.34%
DeepCurrents Investment Group LLC 4,918,000$5,752,0000.17%
KORNITZER CAPITAL MANAGEMENT INC /KS 3,000,000$3,500,0000.05%
CAPSTONE INVESTMENT ADVISORS, LLC 12,500,000$14,646,0000.03%
Citadel Advisors 104,329,000$122,081,0000.03%
LAZARD ASSET MANAGEMENT LLC 20,000,000$23,433,0000.03%
WOLVERINE ASSET MANAGEMENT LLC 2,918,000$3,416,0000.03%
FRANKLIN RESOURCES INC 48,000,000$56,240,0000.02%
View complete list of REVANCE THERAPEUTICS INC shareholders